Etelcalcetide
Etelcalcetide is a peptide calcimimetic: it activates the calcium-sensing receptor to reduce parathyroid-hormone secretion.
At a glance
- Evidence stage
- Approved use
- Regulatory status
- PARSABIV is FDA-approved for secondary hyperparathyroidism in adults with chronic kidney disease receiving hemodialysis.
- Research context
- Etelcalcetide is a peptide calcimimetic: it activates the calcium-sensing receptor to reduce parathyroid-hormone secretion.
What this is
- Etelcalcetide is a peptide calcimimetic: it activates the calcium-sensing receptor to reduce parathyroid-hormone secretion.
What this isn't
- A recommendation to use, prepare, combine, or administer a product
- Evidence that a related molecule or a differently formulated product has the same effects
Key terms
Etelcalcetide is a peptide calcimimetic: it activates the calcium-sensing receptor to reduce parathyroid-hormone secretion.
In advanced kidney disease, disturbed mineral balance can drive persistently high parathyroid hormone. Etelcalcetide activates the parathyroid calcium-sensing receptor, reducing hormone release and often lowering blood calcium. It therefore addresses a dialysis-associated endocrine disorder, not calcium deficiency or a general need to strengthen bones. PARSABIV pharmacology and indication.
Evidence limits
How to read the evidence
A lower PTH value does not demonstrate fewer fractures, fewer cardiovascular events, or longer survival. The label does not recommend extrapolation to primary hyperparathyroidism, parathyroid carcinoma, or kidney disease without hemodialysis. Comparing laboratory response with cinacalcet also does not resolve the balance of symptoms, monitoring burden, and long-term outcomes for an individual patient. Label boundaries; trial conclusion.
Sources appraised 2026-10-28. Educational information; not medical advice. Study findings apply to the populations, preparations and outcomes described.
External sources and citations
Related peptides
Other published briefs in the same research family. Educational references only - not treatment recommendations.
5-Amino-1MQ
When a laboratory value changes but patient outcomes remain uncertain.
Open resourcePeptide brief5-Amino-1MQ / SLU-PP-332
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourcePeptide briefAbaloparatide
How abaloparatide fits into peptide therapeutics, osteoporosis care, and evidence-based bone health.
Open resourcePeptide briefAcetyl hexapeptide-8
Acetyl hexapeptide-8, also called Argireline, is a synthetic cosmetic peptide studied for the appearance of facial lines. Older publications may call the same ingredient acetyl hexapeptide-3.
Open resourcePeptide briefAcetyl octapeptide-3
Acetyl octapeptide-3 is a cosmetic peptide included in products marketed for facial expression lines. Evidence for a delivery system or mixture must be distinguished from evidence for this ingredient alone.
Open resourcePeptide briefAcetyl tetrapeptide-5
Acetyl tetrapeptide-5 is a cosmetic ingredient commonly associated with eye-area products. Laboratory activity is not the same as demonstrated reduction of under-eye puffiness in people.
Open resourceLearn the research basics
Foundational literacy pieces that help interpret evidence stage, product identity, and study design.
How to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceLiteracyWhy a biological mechanism is not a treatment promise
A practical explanation of why plausible pathways still need meaningful human-outcome evidence.
Open resourceLiteracyPeptide naming, aliases, and product identity
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourceLiteracyFrom preclinical finding to human evidence
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourceLiteracyFDA approved, compounded, and unapproved are not synonyms
A plain-language map of product categories that are often blurred in peptide discussions.
Open resourceLiteracyUnderstanding surrogate endpoints in peptide research
When a laboratory value changes but patient outcomes remain uncertain.
Open resourceWatch & read
Same-family videos and articles from the Articles & Media channel. Educational references only.
Preparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resourceArticleAn ingredient name is not a complete product
Why matching a molecule name does not establish sameness in approval, formulation, quality, or evidence.
Open resourceRelated articles
Same-family articles from the published library. Educational references only - not treatment recommendations.
Preparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resourceArticleAn ingredient name is not a complete product
Why matching a molecule name does not establish sameness in approval, formulation, quality, or evidence.
Open resource